

Table of Contents

I. THE CHANGING HEALTH-CARE SYSTEM

Digital Health & Artificial Intelligence

Vanessa K. Burrows and Carolyn V. Metnick

I. Introduction	2
II. Definitions	2
A. Digital Health	2
B. AI	3
III. Regulators	4
IV. Applicable Laws & Guidance	6
A. Digital Health	7
B. AI	9
i. Executive Orders	9
ii. ASTP/ONC's HT-1	10
iii. FDA Guidance, Discussion Papers, and Action Plans	11
iv. EU AI Act	14
v. State Legislation	15
V. Risks	17
A. Digital Health	17
i. Corporate Practice	17
ii. Fee-Splitting	18
iii. Licensure	18
iv. Privacy	19
v. Fraud and Abuse	20
B. AI	20
i. Changes to Business Practices and Increased Governance and Compliance Costs	21

ii. Privacy and Security	21
iii. Liability for Healthcare Providers	21
iv. Bias and Misinformation	23
v. Intellectual Property	24
VI. Enforcement Actions and Litigation	25
A. FTC	25
B. DOJ	26
C. FDA	26
D. HHS OIG	26

Private Equity in the Crosshairs

Matthew S. Miller and Kim Harvey Looney

INTRODUCTION	29
PART 1—UNDERSTANDING PRIVATE EQUITY	31
1.1 The Origins of Modern Private Equity Firms	31
1.2 Private Equity Fund Formation and Operations	33
1.2.1 Structure and Formation	33
1.2.2 Capital Raising	34
1.2.3 Capital Deployment	35
1.2.4 Realization	37
PART 2—THE FOUR EXTERNAL FACTORS THAT INFLUENCE PRIVATE EQUITY	38
2.1 The Crosshairs: A Framework for Analyzing the Four Factors	39
2.2 Economics	41
2.2.1 Economic Cycles and Inflation	41
2.2.2 The Impact of Interest Rates on Private Equity	42
2.2.3 Limitations of the Economic View	44
2.3 Law	45
2.3.1 Corporate Practice of Medicine (CPOM)	46
2.3.2 Stark Law and Anti-Kickback Statute	46
2.3.3 HIPAA and Data Privacy	48
2.3.4 Antitrust Enforcement	50
2.3.5 Post-Closing Liability (RWI)	52

TABLE OF CONTENTS

2.3.6 Limitations of the Legal View	53
2.4 Politics and Philosophy	54
2.4.1 The Growing Disconnect from Consumers	54
2.4.2 Ethics and Innovation	55
2.4.3 Limitations of the Political and Philosophi- cal Viewpoints	56
PART 3—TAKING AIM AT PRIVATE EQUITY'S FUTURE	57
3.1 Where Things Stand Today	57
3.1.1 Private Equity is Still Relatively New in Healthcare	59
3.1.2 Healthcare Private Equity Must Face Bad Facts	61
3.1.3 State Legislation Continues to Evolve	64
3.1.4 Federal Litigation and Antitrust Enforce- ment	65
3.2 The Jury is Still Out on Private Equity in Healthcare	67
3.3 The “Four Factors” Provide a Guide	70
CONCLUSION	71

Top Trends in Antitrust Merger Enforcement and Beyond: A Look Back and Forward

Wendy Arends

I. Introduction	73
II. Antitrust Agencies' Changes to M&A Policies, Guidelines, and Enforcement	76
III. Putting Principles into Action: Antitrust Trends in Merger Enforcement and Beyond	82
IV. Conclusion	97

II. TRANSACTIONAL ISSUES

Representations and Warranties in

Healthcare Transactions

Ari J. Markenson and Christopher Conn

1. Introduction	101
2. Major Areas Covered by Healthcare-Specific Representations and Warranties	104
a. Compliance with Defined “Healthcare Laws”	104
b. Reimbursement	105
c. Fraud and Abuse	107
d. Licensure	108
e. Excluded Parties	109
f. Privacy	110
g. Regulatory Compliance Programs	112
3. Representation and Warranty Qualifiers	113
a. Knowledge Qualifiers	113
b. Materiality Qualifiers	114
c. Look-back Periods	115
d. Survival Periods	117
4. Conclusion	118
MODEL—Healthcare Matters—Representations and Warranties of the Seller	118
MAJOR DEFINITIONS	125

Implementing Alternative Dispute Resolution Concepts in Healthcare

Christopher Sabis and Gary Qualls

I. WHAT IS ADR AND WHAT DOES THIS CHAPTER ADDRESS ABOUT IT?	131
II. WHAT GOVERNS ARBITRATION	132
A. Arbitration is the Mode of Dispute Resolution Only If the Parties Agree to It	132
B. What Law or Rules Govern Arbitration.	132
1. The Agreement.	132
2. Statutes.	133
3. Rules.	134

TABLE OF CONTENTS

III. WHETHER TO CHOOSE ARBITRATION	134
A. Why You Might Want to Select Arbitration vs. Court Litigation	134
1. Expert Tribunal	134
2. Expedited Process	135
3. Finality	135
4. Providing Award Flexibility.	137
5. Limiting Award Flexibility.	137
6. Confidentiality.	137
7. Allocating Costs and Attorneys' Fees	139
8. Creative Methods Such as Baseball Arbitration	139
B. Why You Might Want Court Litigation vs. Arbitration	139
IV. HOW TO TAILOR YOUR ADR	140
A. Mandatory or Opt-Out ADR	143
1. Options	143
2. Considerations	143
3. Recommendations	144
B. Statement of Purpose	145
1. Options	145
2. Considerations	146
3. Recommendations	147
C. Venue and Applicable Law	148
1. Options	148
2. Considerations	148
3. Recommendations	150
D. Scope of ADR clause	152
1. Options	152
2. Considerations	152
3. Recommendations	153
E. Mediation	154
1. Options	154
2. Considerations	155
3. Recommendations	155
F. Applicable Rules/ADR Provider	156
1. Options	156
2. Considerations	157

3. Recommendations	158
G. Arbitrator Selection	158
1. Options	158
2. Considerations	159
3. Recommendations	161
H. Scope of Discovery	163
1. Options	163
2. Considerations	164
3. Recommendations	166
I. Form and Scope of Award	167
1. Options	167
2. Considerations	167
3. Recommendations	168
J. Allocation of fees and costs	169
1. Options	169
2. Considerations	170
3. Recommendation	170
K. Appeal Clause	171
1. Options	171
2. Considerations	172
3. Recommendations	173
V. CONCLUSION	174

History Doesn't Repeat Itself, but It Often Rhymes: The Evolving Role of Non-Competes in Healthcare and How Their Past Informs Their Future

Jantzen D. Mace and Samuel N. Lillard

1. Introduction	176
2. Historical Use and Enforcement of Non-Competition Agreements	176
2.1 Early Use and the Legal Foundations on the Balance of Competing Interests	176
2.2 Evolution in the United States	179

TABLE OF CONTENTS

3. The Rise and Role of Non-Competes in Healthcare—to Ban or Not to Ban?	183
3.1 The American Medical Association’s Historical Stance(s) on Non-Competes	183
3.2 The Argument for Allowing Non-Competes in Healthcare	187
3.3 The Argument for Banning Non-Competes in Healthcare—Harm to Physicians	190
3.4 The Argument for Banning Non-Competes in Healthcare—Harm to Patients	191
4. Federal Regulatory Attempts to Ban or Restrict the Use of Non-Competes	192
4.1 Precursors to the FTC’s 2024 Final Rule—Regulation of Anti-Competitive Practices in Job Training and the Attack Against the AMA	193
4.2 The Federal Trade Commission’s 2023 and 2024 Attacks on Non-Competes	196
4.3 The NLRB’s 2023 and 2024 Attacks on Non-Competes	200
5. State-Level Reforms to Limit Non-Competes	203
6. The Future of Non-Competes In Healthcare	204
7. Conclusion	206

III. REIMBURSEMENT AND PAYMENT

Provider-Based Payment

Christina A. Hughes

I. Overview	210
II. Requirements for PBS	212
A. Location	213
B. Corporate Structure and Operational Organization	215
C. Provision of Services	216
D. Other Considerations	217
1. Public Awareness	217

2. Management and Under-Arrangement Contracts	217
3. Joint Ventures	219
4. Enrollment	220
III. Advantages	220
A. Higher Reimbursement Rates	221
B. Access to Hospital Resources	222
C. Bad Debt and Uncompensated Care	222
1. Bad Debt	223
2. Uncompensated Care:	223
D. Graduate Medical Education Payments	224
1. Residents Working at Provider-Based Facilities	225
2. Key Considerations	225
E. Inclusion in the Main Provider's Licensure, Contracts, Etc.	226
F. 340B Eligibility	226
IV. Disadvantages	227
A. Site-Neutral Payments	227
1. How Site-Neutral Payment Works	228
2. Impact on Off-Campus Provider-Based Facilities	228
B. Stringent and Complicated Requirements with Big Consequences	229
C. Patient Confusion and Dissatisfaction	230
D. Physician Dissatisfaction	231
V. Interaction with Other Payors	234
VI. Conclusion	235

The “State Actor” Question: Navigating Section 1983 Civil Rights Claims Involving Medicaid Managed Care Organizations

Andrea Kerstein, Heidi Brady, and Alyssa Gregory

I. The Unique Role of Medicaid MCOs in State Medicaid Programs	239
--	-----

TABLE OF CONTENTS

II. Section 1983's General Requirements	241
III. The "State Action" Requirement's General Applica- tion to Private Parties	242
A. The "Public Function" Test	244
B. The "State Compulsion" Test	245
C. The "Nexus" / "State Action" / "Joint Action" Test	246
D. The "Entwinement" Test	248
IV. How The State-Action Requirement Has Been Ap- plied to MCOs	249
A. Decisions in the 1990s	250
B. Decisions in the Early 2000s	251
C. Decisions in the 2010s	253
D. Decisions in the 2020s	258
V. Considerations For Cases Involving the "State Ac- tion" Requirement and MCOs	259

Overpayments

Susan Banks

I. Introduction	264
II. The Federal Overpayment Statute	265
III. Legal Background and Context	267
A. Before the Overpayment Statute	268
B. Enforcement Under the Overpayment Statute: CMPs and FCA Liability	270
IV. Down to Brass Tacks: Mechanics of the Overpay- ment Statute	273
A. The Report and Return Requirement	273
B. "Lookback Period"	274
C. Definition of "Identified"	276
1. A Trip Down Memory Lane	276
2. The Demise of Reasonable Diligence	280
3. Current Lay of the Land: The New Rule	282
V. What is an "Overpayment"?	290
A. Conditions of Participation Versus Conditions of Payment	290

B. Landmark Supreme Court Cases: Tools for the Toolkit	293
1. Escobar	293
2. Allina	297
3. SuperValu	303
4. Loper Bright	306
5. Kisor	38
VI. Overpayment Considerations for Different Payor Sources	311
A. Payments from Medicaid FFS Programs	311
B. Payments from Medicare Advantage Organizations and Medicaid Managed Care Organizations ..	312
C. Payments from Federal Health Care Program Beneficiaries	314
VII. Key Takeaways for Providers	318

Know Your Audit! Operational Considerations Under Every Kind of Audit

Lindsey Lonergan, Ross Burris, and Evan Schrode

I. Understanding the Audit Landscape	322
A. Introduction: They're All Watching You!	322
B. The Framework of Government Healthcare Audits: The Auditors	323
C. The Framework of Government Healthcare Audits: Audit Types	327
D. Targeted Probe and Educate Audits	328
E. Medicare Payment Suspension	329
II. Identifying and Returning Overpayments	331
A. The 60-day Rule	331
B. Reporting and Returning an Overpayment	333
III. Audit Defense	334
A. Medicare Appeals Process	334
B. The Importance of Audit Defense	338
IV. Proactive Strategies for Successful Audit Defense ..	340

TABLE OF CONTENTS

A. Implement a Multi-Disciplinary Audit Response Team	340
B. Inventory internal resources to determine what external resources you may need to respond to an audit	341
C. Educate All Employees Regarding Routing of Government Communications	342
D. Ensure your organization's full participation in audit processes and vigorously defend all denials .	343
E. Perform Meaningful Internal Audits	345
F. Evaluate organizational contracts and agreements	346
V. Closing Thoughts	347

IV. REIMBURSEMENT AND PAYMENT

Healthcare Fraud and Abuse Update

Taylor Chenery, John Eason, and Travis Lloyd

I. Introduction	350
II. Anti-Kickback Statute and Stark Law—Regulatory Developments	351
1. OIG Updates	351
A. General Nursing Facility Compliance Program Guidance	351
B. Special Fraud Alert on Medicare Advantage Marketing Arrangements	352
C. OIG Advisory Opinions	354
2. CMS Updates	356
A. Overpayment Rule Revisions	356
B. Self-Referral Disclosure Protocol Settlements ...	359
III. Anti-Kickback Statute and Stark Law—Key Court Decisions	361
1. Anti-Kickback Statute—Causation	361
2. Anti-Kickback Statute—Intent	363

3. Stark Law—Impact of <i>Loper Bright</i>	365
IV. Anti-Kickback Statute and Stark Law—Noteworthy Settlements	366
1. Hospital/Physician Kickback Schemes	366
2. Other Noteworthy Settlements	368
V. False Claims Act Developments	371
1. Constitutionality of Qui Tam Provision	371
2. Pleading Submission of Claims and Fraudulent Scheme	372
3. Pleading and Proving Falsity	374
4. Pleading and Proving Materiality	376
5. Knowledge/Scienter	379
6. Public Disclosure Bar	382
7. FCA Damages	385
8. FCA Retaliation	388
9. Healthcare Fraud—Criminal Enforcement	390

Beyond FaceTime v.2.0: The OIG Awakens

Alice G. Gosfield

Introduction	393
1.0 Early Non-FaceTime Services Chronologically	394
1.1 “Incident to”	394
1.2 Care Plan Oversight	398
1.3 Split/Shared Visits	400
2.0 Today’s Coordination of Care Codes	402
2.1 Transitional Care Management	403
2.2 Chronic Care Management	406
2.3 Remote Physiologic Monitoring	411
2.3 Advanced Primary Care Management Services ..	414
3.0 Enforcement Risks Given Caselaw	417
3.1 Escobar	418
3.2 Allina	420
3.3 Loper Bright	422
4.0 Conclusion	424

TABLE OF CONTENTS

Medicare Enrollment Defenses: Regs, Forms, and the Supreme Court

Daniel F. Shay

Introduction	425
1.0 Enrollment History	426
1.1 2001 to 2009	427
1.2 2010 and Increased Scrutiny	429
1.3 Enrollment Form Changes	431
2.0 Advising Clients on Medicare Enrollment Matters	433
2.1 The General Advice Approach	433
2.2 The Legal Defense Approach	434
2.3 Allina in the Defense Context	434
2.4 Escobar in the Defense Context	437
3.0 Regulatory Hierarchy Overview	441
3.1 The Forms	441
3.2 The Manuals	442
3.3 Why Does the Hierarchy Matter?	449
4.0 Practical Advice & Real-World Scenarios	454
4.1 Scenario 1: Harry Doesn't Work Here Anymore ..	456
4.2 Scenario 2: Lost in the Mail	457
4.3 Scenario 3: Reassignment Whistleblower	458
5.0 Conclusion	460

Use of Clinical Validation in Health Plan Program Integrity: Intersection of Coding, Practice of Medicine, and Utilization Management

Richelle D. Marting

I. Introduction	463
II. Background	464
III. Code Assignment	467

A. Background of International Classifications of Diseases (ICD) and Diagnostic Related Groups (DRGs)	467
B. Assigning ICD Diagnosis and Procedure Codes to a Medical Record	469
C. Assigning a Diagnostic Related Group (DRG)	470
IV. Ensuring Accuracy through Validation	473
A. DRG Validation	473
B. Clinical Validation	475
V. Outcome of DRG and Clinical Validation: Denial or Adjustment	477
A. Claim Adjustment Reason codes (CARC) and Remittance Advice Remark Codes (RARC)	478
B. Development CARC and RARC Combination Rules	480
C. Selection of CARC and RARC: Adjustment or Denial	482
VI. A Further Examination of DRG Validation Determinations and Their Classification	485
VII. A Further Examination of Clinical Validation Determinations and Their Classification	487
VIII. Transparency in Health Plan Communication of DRG and Clinical Validation Findings	490
IX. Implications of Clinical Validation as a Denial of Coverage	494
A. Examination of the Definition for the Practice of Medicine	494
B. Utilization Review Activities Must be Performed by Qualified Reviewers	497
C. Utilization Review Activities Must be Made Using Appropriate Criteria	499
D. Clinical Validation Decisions as Utilization Review Decisions	500
E. Clinical Validation in Practice	501
X. Burden of Proof in Utilization Management: The Treating Physician Rule	504
XI. Conclusion	507

TABLE OF CONTENTS

Table of Cases
Index